CivaTech Oncology, Inc. received FDA market clearance in September, 2008 for a low-dose-rate, linear brachytherapy device, called CivaString. The device is initially focused on the treatment of prostate cancer using a radioactive polymer concept. The LDR brachytherapy product will provide superior treatment of prostate cancer. The device is approved for treatment of localized tumors and the Company is also targeting breast and lung cancers. For more information, go to www.civatechoncology.com
|
|
|
|
|
|